Horizon Therapeutics Public Limited (NASDAQ:HZNP) CEO Timothy P. Walbert Sells 25,000 Shares

Horizon Therapeutics Public Limited (NASDAQ:HZNP) CEO Timothy P. Walbert sold 25,000 shares of Horizon Therapeutics Public stock in a transaction dated Friday, April 30th. The stock was sold at an average price of $94.98, for a total value of $2,374,500.00. Following the sale, the chief executive officer now directly owns 920,710 shares of the company’s stock, valued at approximately $87,449,035.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

NASDAQ HZNP opened at $92.80 on Tuesday. Horizon Therapeutics Public Limited has a 1 year low of $35.04 and a 1 year high of $97.20. The stock has a market capitalization of $20.79 billion, a PE ratio of 25.36, a PEG ratio of 0.59 and a beta of 1.15. The company has a debt-to-equity ratio of 0.26, a current ratio of 3.49 and a quick ratio of 3.39. The business’s 50-day moving average is $90.63 and its 200 day moving average is $81.13.

Horizon Therapeutics Public (NASDAQ:HZNP) last released its quarterly earnings data on Tuesday, February 23rd. The biopharmaceutical company reported $1.28 earnings per share for the quarter, topping the consensus estimate of $1.06 by $0.22. Horizon Therapeutics Public had a return on equity of 25.66% and a net margin of 43.55%. The business had revenue of $745.31 million during the quarter, compared to analysts’ expectations of $694.20 million. As a group, equities research analysts anticipate that Horizon Therapeutics Public Limited will post 3.21 earnings per share for the current year.

A number of equities analysts recently weighed in on HZNP shares. Citigroup raised their price objective on Horizon Therapeutics Public from $116.00 to $120.00 in a report on Thursday, March 18th. Wolfe Research began coverage on shares of Horizon Therapeutics Public in a research note on Wednesday, March 17th. They set an “outperform” rating and a $107.00 price target on the stock. Morgan Stanley reaffirmed an “overweight” rating and issued a $103.00 price objective on shares of Horizon Therapeutics Public in a research note on Monday, March 29th. Bank of America reiterated a “buy” rating and issued a $100.00 target price on shares of Horizon Therapeutics Public in a research report on Tuesday, February 9th. Finally, Jefferies Financial Group restated a “buy” rating and set a $120.00 price target on shares of Horizon Therapeutics Public in a research report on Friday, March 19th. One research analyst has rated the stock with a hold rating and eleven have given a buy rating to the stock. Horizon Therapeutics Public currently has a consensus rating of “Buy” and a consensus target price of $110.08.

Several large investors have recently bought and sold shares of the company. BlackRock Inc. boosted its stake in shares of Horizon Therapeutics Public by 23.0% during the 4th quarter. BlackRock Inc. now owns 14,206,978 shares of the biopharmaceutical company’s stock valued at $1,039,241,000 after purchasing an additional 2,653,855 shares in the last quarter. Avoro Capital Advisors LLC lifted its holdings in Horizon Therapeutics Public by 17.6% in the fourth quarter. Avoro Capital Advisors LLC now owns 9,000,000 shares of the biopharmaceutical company’s stock worth $658,350,000 after buying an additional 1,350,000 shares during the period. JPMorgan Chase & Co. boosted its position in Horizon Therapeutics Public by 23.1% during the 4th quarter. JPMorgan Chase & Co. now owns 5,907,934 shares of the biopharmaceutical company’s stock valued at $432,166,000 after acquiring an additional 1,107,324 shares in the last quarter. Viking Global Investors LP grew its holdings in shares of Horizon Therapeutics Public by 212.1% during the 4th quarter. Viking Global Investors LP now owns 3,662,876 shares of the biopharmaceutical company’s stock worth $267,939,000 after acquiring an additional 2,489,132 shares during the period. Finally, Norges Bank bought a new position in shares of Horizon Therapeutics Public in the 4th quarter worth approximately $122,990,000. 88.59% of the stock is owned by hedge funds and other institutional investors.

About Horizon Therapeutics Public

Horizon Therapeutics Public Limited Company focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. It operates in two segments, Orphan and Inflammation. Its medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare lysosomal storage disorder; ACTIMMUNE for chronic granulomatous disease and severe malignant osteopetrosis; RAYOS for the treatment of rheumatoid arthritis (RA), ankylosing spondylitis (AS), polymyalgia rheumatica, primary systemic amyloidosis, asthma, chronic obstructive pulmonary disease, systemic lupus erythematosus, and other conditions; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.

Featured Story: Dividend Aristocrat Index

Insider Buying and Selling by Quarter for Horizon Therapeutics Public (NASDAQ:HZNP)

Receive News & Ratings for Horizon Therapeutics Public Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics Public and related companies with MarketBeat.com's FREE daily email newsletter.